FREMONT, Calif.--(BUSINESS WIRE)--FlowMedica Inc., a medical device company pioneering targeted renal therapy (TRT®), today announced the release of the Benephit® XT Infusion System, a next-generation infusion system designed for implementing TRT – the direct delivery of physician-specified medications and other therapeutic agents to the kidneys via the renal arteries. TRT is an alternative to the standard delivery method of systemic intravenous (IV) infusion of physician-specified agents. It may offer significant benefit via direct infusion of therapeutic levels of medications without the side effects that can be encountered with conventional IV delivery. Physicians are employing TRT to address major causes of kidney failure. These causes include contrast-induced nephropathy (CIN), cardiorenal syndrome and other forms of acute kidney injury (AKI).
